Ken A. Brameld - Concepedia

Author

Ken A. Brameld

Principia Biopharma (United States)ORCID

Also Known As

Brameld, Kenneth A., K. Brameld, K.A. Brameld, Ken A Brameld, Ken A. Brameld, Ken Brameld, Kenneth A. Brameld

Publications

2.4K

Citations

H-Index

Concepts

All Affiliations

Principia Biopharma (United States)California Institute of Technology La Roche College University of California, Irvine Roche (Switzerland)

About

Ken A. Brameld is an author at Principia Biopharma (United States) specializing in natural sciences, medicine, and drug discovery.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	10	10	808
2	Natural Sciences	10	10	888
3	Biochemistry	6	6	699
4	Engineering	2	2	33
5	Applied Physics	1	1	19

Ken A. Brameld

Publications

1.7K

Citations

H-Index

Page 1

	Year	Citations
Prolonged and tunable residence time using reversible covalent kinase inhibitors J. Michael Bradshaw, Jesse M. McFarland, Ville O. Paavilainen, Nature Chemical Biology Medicinal ChemistryBiochemistryMedicineNatural SciencesTunable Residence Time	2015	422
Substrate assistance in the mechanism of family 18 chitinases: theoretical studies of potential intermediates and inhibitors 1 1Edited by B. Honig Ken A. Brameld, William D. Shrader, Barbara Imperiali, Journal of Molecular Biology Bioorganic ChemistryBiochemistryB. HonigNatural SciencesSubstrate Assistance	1998	111
The role of enzyme distortion in the single displacement mechanism of family 19 chitinases Ken A. Brameld, William A. Goddard Proceedings of the National Academy of Sciences	1998	108
Preclinical Efficacy and Anti-Inflammatory Mechanisms of Action of the Bruton Tyrosine Kinase Inhibitor Rilzabrutinib for Immune-Mediated Disease Claire L. Langrish, J. Michael Bradshaw, Michelle Francesco, The Journal of Immunology	2021	108
The chitinase PfCHT1 from the human malaria parasite <i>Plasmodium falciparum</i> lacks proenzyme and chitin-binding domains and displays unique substrate preferences Joseph M. Vinetz, Sanat K. DAVÉ, Charles A. Specht, Proceedings of the National Academy of Sciences	1999	107
Distance Dependent Hydrogen Bond Potentials for Nucleic Acid Base Pairs from <i>ab Initio</i> Quantum Mechanical Calculations (LMP2/cc-pVTZ) Ken A. Brameld, Siddharth Dasgupta, William A. Goddard The Journal of Physical Chemistry B Natural SciencesChemical BondHydrogen BondMolecular BiologyHydrogen-bonded Liquid	1997	101
Discovery of the Irreversible Covalent FGFR Inhibitor 8-(3-(4-Acryloylpiperazin-1-yl)propyl)-6-(2,6-dichloro-3,5-dimethoxyphenyl)-2-(methylamino)pyrido[2,3-<i>d</i>]pyrimidin-7(8<i>H</i>)-one (PRN1371) for the Treatment of Solid Tumors Ken A. Brameld, Timothy D. Owens, Erik Verner, Journal of Medicinal Chemistry Drug TargetSolid TumorsPharmacotherapyFgf/fgfr PathwayPotent Fgfr1-4 Inhibitor	2017	95
Substrate Distortion to a Boat Conformation at Subsite −1 Is Critical in the Mechanism of Family 18 Chitinases Ken A. Brameld, William A. Goddard Journal of the American Chemical Society Bioorganic ChemistryProtein AssemblyMolecular BiologyChemical BiologyEnzymatic Modification	1998	91
Ab Initio Quantum Mechanical Study of the Structures and Energies for the Pseudorotation of 5‘-Dehydroxy Analogues of 2‘-Deoxyribose and Ribose Sugars Ken A. Brameld, William A. Goddard Journal of the American Chemical Society	1999	77
Discovery of Reversible Covalent Bruton’s Tyrosine Kinase Inhibitors PRN473 and PRN1008 (Rilzabrutinib) Timothy D. Owens, Ken A. Brameld, Erik Verner, Journal of Medicinal Chemistry	2022	65

Page 1